ArriVent Is Second Positive IPO Of 2024 After CG Oncology’s Debut

Cancer Drug Developer Closes Up 11.1%

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

ArriVent launched the second biopharma initial public offering of 2024, closing above its IPO price on its first day and grossing $175m – and keeping the financial market mood optimistic.

Skyscrapers Cityscape Downtown View, Boston Skyline Buildings. NIght time. IPO hologram.
The positive performance of the year's first two IPOs may drive future offerings • Source: Shutterstock

ArriVent Biopharma, Inc. launched the second biopharmaceutical company initial public offering of 2024, a day after CG Oncology, Inc. became the first drug developer to go public in the US this year. While ArriVent did not almost double its valuation in its first day of trading like its predecessor, the company’s IPO was well received, with its share price closing above the offering price in its first day of trading – another positive sign that investors are feeling confident about the industry again.

Key Takeaways

  • ArriVent launched an upsized offering in the middle of a proposed price range to gross $175m in the second biopharma IPO in the US for 2024.

Newtown Square, PA-based ArriVent sold 9.72 million shares at $18 each to gross $175m late on 25 January, which was...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.